ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

FDBK Feedback Plc

60.50
0.00 (0.00%)
19 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Feedback Plc LSE:FDBK London Ordinary Share GB00BJN59X09 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 60.50 60.00 61.00 60.50 60.50 60.50 14,770 07:44:37
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Electronic Computers 1.03M -2.92M -0.2188 -2.77 8.07M
Feedback Plc is listed in the Electronic Computers sector of the London Stock Exchange with ticker FDBK. The last closing price for Feedback was 60.50p. Over the last year, Feedback shares have traded in a share price range of 58.00p to 150.00p.

Feedback currently has 13,334,659 shares in issue. The market capitalisation of Feedback is £8.07 million. Feedback has a price to earnings ratio (PE ratio) of -2.77.

Feedback Share Discussion Threads

Showing 8176 to 8199 of 14875 messages
Chat Pages: Latest  331  330  329  328  327  326  325  324  323  322  321  320  Older
DateSubjectAuthorDiscuss
17/3/2020
23:36
Bleepa is the only communications platform that allows clinicians to share & discuss patient cases using clinical-grade imaging on their personal devices. We provide #NHS staff with the tools they need to work safely&remotely. We are here to support during #coronavirusOutbreak
ged5
17/3/2020
23:34
Thanks @rijan44
. We are offering @BleepaMe for free to any #NHS Trust that need a remote image sharing and communication solution to protect staff during the coronavirus outbreak. We are answering the call and looking to help



That's the way to go Tom. Good lad! Hope they take you up on this.

ged5
16/3/2020
16:26
Predicting Outcome In Childhood Diffuse Midline Gliomas Using Magnetic Resonance Imaging Based Texture Analysis



METHODS: Retrospective study of patients diagnosed with DMG, based on radiological features, treated at our institution 2007-2017. MRIs were acquired at diagnosis and 6 weeks after radiotherapy (54Gy in 30 fractions). MRTA was performed using commercial available TexRAD research software on T2W sequence and Apparent Diffusion Coefficient (ADC) maps encapsulating tumour in the largest single axial plane. MRTA comprised filtration-histogram technique using statistical and histogram metrics for quantification of texture. Kaplan-Meier survival analysis determined association of MRI texture parameters with OS.

lr2
16/3/2020
16:22
Yep, that's what it looked like to me.
lr2
16/3/2020
15:56
Looking at the tiny price difference now, maybe it was just someone moving a holding between different wrappers
davydoo
16/3/2020
10:19
wow. 2 stonking buys at 0.60 earlier this morning
davydoo
15/3/2020
18:19
Best to restrict your travelling to quiet times to avoid contact with other people as much as possible.

I've had flu twice. It's completely debilitating. All you can do is keep the temperature down, sleep as much as possible and drink water. Too many people confuse a bad virus with flu.

Now is the time to get Bleepa out to the front line in as many places as possible. If it's liked then the sales will come

It would be quite ironic if TexRAD became the main product for Feedback!

Take care.

ged5
15/3/2020
16:04
Just popped in from planting some spuds and saw your post. Thanks LR2.

"An international collaboration has recently begun working on a standardization for extraction of image biomarkers in radiomics"

Perhaps TexRAD might come back to the fore.

Coronavirus attacks the lungs

TexRAD lung may have a part to play.

Surely Bleepa could be useful in this crisis.

Is your sister being isolated? Is she considered one of the vulnerable ones?

ged5
15/3/2020
15:02
Firstly, only a few clinical software packages are currently available (Dosisoft, OncoRadiomics, TexRad), although a larger number will undoubtedly emerge in the future. Interestingly, some research tools are free of charge (IBEX, CGITA, CERR, QMaZda, LifeX, Pyradiomics, RaCaT) allowing more easily the spreading of radiomics among medical community.
lr2
13/3/2020
17:23
Expect it to be cancelled or postponed davy.
ducatiman
13/3/2020
14:51
Thanks. That#s just around the corner from me, so I will go and err feedback
davydoo
13/3/2020
14:13
Let’s hope they have something to say
ducatiman
13/3/2020
13:51
Feedback presenting in London on 26th March.



(Remove hyphen)

ged5
13/3/2020
09:48
I bought 500k at .46 last night 500k at .45 this morning

Hopefully this is the bottom here.

I see a resignation in my clients to just accept this now. No ones selling With some buying interest

davydoo
12/3/2020
16:57
If Directors have money to spend theyll be earmarking it for a future fund raise, they'll need that capital, buying shares off a disgruntled holder will do nothing
davydoo
12/3/2020
16:50
Don't think director buying will make any difference here for now. Instead of spending time om you tube they should be updating the market with an RNS on how the trial was progressing, what other collaborations have being going on in the background etc.
digger2779
12/3/2020
16:24
Wonder if any directors think this is cheap enough for them to buy any shares? I don't own any of these now but this is a truly shocking SP
dplewis1
12/3/2020
14:18
Companies that need to raise in this environment are the ones in the most trouble. Need a contract now.
czc9
12/3/2020
14:05
the issue now becomes not just will they deliver but can they raise again before they do
davydoo
12/3/2020
12:35
And flush!
ducatiman
10/3/2020
12:50
CE Mark can’t be far off.
ducatiman
10/3/2020
09:30
LOL

FDBK need good sales people.

ged5
10/3/2020
09:23
Buy now! special offer! 50% off the recent placing price!
davydoo
09/3/2020
20:15
If further funds are required to pay running expenses and orders are coming in the near future, then why dilute the share? Surely an overdraft facility would do the job
sonie01
Chat Pages: Latest  331  330  329  328  327  326  325  324  323  322  321  320  Older